ArticleLiver international : official journal of the International Association for the Study of the Liver2026
p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV-Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- p38 Inhibitor SB203580 Inhibits HEV Infection and Prevents HEV-Related Adverse Pregnancy Outcomes in a Pregnant Rabbit Model.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsHepatitis E virus (HEV) infection during pregnancy can lead to severe adverse pregnancy outcomes including stillbirth, preterm birth, abortion, maternal death, and vertical transmission. Off-label use of ribavirin or pegylated interferon-α is proved effective for treating HEV infection, but they are both contraindicated for pregnant women. A safe and effective treatment against HEV infection during pregnancy is urgently needed.
methodsWe used JEG-3 choriocarcinoma cells to investigate the p38-MAPK signalling pathway in HEV replication. The cells were treated with varying concentrations of SB203580, a selective p38-MAPK inhibitor. For in vivo validation, HEV-infected pregnant rabbits were treated with SB203580. HEV replication, cytokine secretion, apoptosis, and pathological changes were measured. The effects on pregnancy outcomes, including vertical transmission, were also monitored.
resultsIn this study, with a HEV-infected choriocarcinoma cell line, the JEG-3 cell model, we found that HEV infection significantly altered the expression patterns of the p38-MAPK signalling pathway. SB203580 can inhibit HEV replication and reduce the secretion of proinflammatory cytokines and apoptosis in vitro. Further in vivo validation with the HEV-infected pregnant rabbit model also revealed that SB203580 treatment during pregnancy significantly reduced the viral load in faeces and serum, the secretion of proinflammatory cytokines, and apoptosis in placental tissues. Most importantly, SB203580 is not only safe but can also effectively prevent HEV-related adverse pregnancy outcomes in pregnant rabbits and vertical transmission of HEV to pups.
conclusionsThese results demonstrate that the p38 inhibitor SB203580 is an effective compound with potential as a therapeutic candidate against HEV infection during pregnancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.